Bruker and Purity-IQ Partner to Transform Cannabis Regulatory Landscape
Bruker and Purity-IQ announced their joint partnership with a goal to create a new testing system aimed at helping the medical cannabis industry in Canada.
In a recent press release, Bruker (Billerica, Massachusetts) and Purity-IQ (Mississauga, Canada) announced their joint partnership with a goal to create a new testing system aimed at helping the medical cannabis industry in Canada (1). The Purity-IQ Cannabis Fingerprint incorporates Bruker’s expertise in nuclear magnetic resonance (NMR) based screening technology with Purity-IQ’s genomics capabilities to provide traceability and identity testing throughout the cannabis supply chain.
Currently, there are no standardized regulations in effect between states or countries to regulate quality control in cannabis. Without these regulations in place, it makes it difficult for consumers to make informed decisions about the products they are buying. According to the two companies, uniting these technologies will help give the supply chain an opportunity to progress the cannabis industry forward to a consistent and compliant platform.
With regulatory standards continuously shifting, cannabis producers and manufacturers need to be able to ensure product quality and consistency of strain and dosage. Also affected are the retailers such as pharmacies and dispensaries who need to protect their brand and offer consumers a product that can be trusted.
According to the press release, identifying the genomic profile and chemical compounds in a cannabis cultivar is the key to being able to ensure dosing assurance and consistent quality. Genomics are used to establish cannabis identity and heredity. NMR identifies the consistency and purity of the product at a molecular level, which offers traceability, authenticity, and identity throughout the supply chain from plant to finished product. This creates a unique chemical “fingerprint,” using the Purity-IQ Global Cannabis Registry to devise new Cannabis Authenticity and Purity Standards (CAPS).
In addition, the announcement stressed the advantages of using NMR compared to other technologies available on the market. NMR is an untargeted analysis method that reportedly provides an extensive view on the metabolome. With the use of NMR, it allows for an easier determination of the relative concentration of substances in a mixture accurately and rapidly.
“A genetic fingerprint alone is not enough to produce a full picture. To generate a complete fingerprint, cannabis strains must also be profiled using NMR technology,” said Dr. Henry Stronks, President of Bruker Canada, in the press release (1). “Pattern recognition allows us to identify peaks that correspond to the pharmacological properties of the cannabis, its geographical location, strain, hybrid and quality. We believe this is the first step for the cannabis industry in providing safe, uniform and effective products founded in combined genomics and metabolomics testing.”
Terry Dennis, Chief Marketing Officer at Purity-IQ also commented on the collaboration with Bruker (1). “CAPS recognition will identify and differentiate products, build intellectual property, ensure authenticity, drive confidence in product quality claims, allow access to new markets, and protect brand reputation. There is a whole host of other sectors that would benefit from the combination of genetic and metabolomic fingerprinting, particularly in the food and beverage industry in the fight against food fraud,” said Dennis. “This will support the whole value chain and, one day, consumers will have full transparency, trust and confidence in all products they buy.”
Through this newly formed partnership, both Bruker and Purity-IQ plan to apply their technology to better aid the cannabis industry and promote consistency along with compliancy. Bruker’s 400 MHz NMR spectrometer and its Fourier 80 benchtop NMR system are installed at the University of Guelph in Canada, where Bruker’s and Purity-IQ’s scientists plan to collaborate in research and development with the Natural Health Products (NHP) Research Alliance. The NHP is a collaborative body based at the University of Guelph, creating novel DNA-based ingredient identity tools founded on a global standard biological reference materials DNA library for natural health products.
Reference:
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Khan
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Khan
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
